 |
23 Diseases |  |
21 Trials |
|
21 Trials |  |
1283 News |  |
| «12...56789101112131415...1617» |
- | Imlygic (talimogene laherparepvec) / Amgen
Enrollment open, Metastases: Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma (clinicaltrials.gov) - Nov 13, 2020
P2, N=15, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Recruiting
- || eptifibatide! ixekizumab! ixabepilone! TALIMOGENE LAHERPAREPVEC (Twitter) - Nov 10, 2020
- || Reolysin (pelareorep) / Oncolytics, Andrus Reo
Review, Journal, Oncolytic Virus: Past, Present and Future of Oncolytic Reovirus. (Pubmed Central) - Nov 5, 2020
This article will provide an unbiased review of oncolytic reovirus (clinically formulated as pelareorep), including the molecular and cellular requirements for reovirus oncolysis and anti-tumour immunity, reports of pre-clinical efficacy and its overall clinical trajectory. Moreover, as it is now abundantly clear that the true potential of all OVs, including reovirus, will only be reached upon the development of synergistic combination strategies, reovirus combination therapeutics will be discussed, including the limitations and challenges that remain to harness the full potential of this promising therapeutic agent.
- | Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Tumor mutational burden, IO biomarker, Metastases: S1607: Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov) - Nov 5, 2020
P2, N=47, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Moreover, as it is now abundantly clear that the true potential of all OVs, including reovirus, will only be reached upon the development of synergistic combination strategies, reovirus combination therapeutics will be discussed, including the limitations and challenges that remain to harness the full potential of this promising therapeutic agent. Recruiting --> Active, not recruiting
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date: Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Oct 29, 2020
P2, N=112, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial completion date: Sep 2020 --> Mar 2021
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTURL] 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma () - Oct 24, 2020 - Abstract #SITC2020SITC_1869;
- Libtayo (cemiplimab) / Sanofi, Regeneron
[VIRTUAL] Successful Clinical Application of Intratumoral Injection of Influenza Vaccine to Sensitize Metastatic Cutaneous Squamous Cell Carcinoma to Cemiplimab and Radiotherapy () - Oct 23, 2020 - Abstract #ASDS2020ASDS_263;
The influenza vaccine is priced at less than US $100, while the cost for a course of TVEC is approximately US $65,000. Formal studies are needed evaluating the clinical efficacy of intratumoral injection of Flubok Quadrivalent recombinant influenza vaccine in CSCCs as well as other tumors.
- | Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date, Combination therapy: Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases (clinicaltrials.gov) - Oct 22, 2020
P1b, N=36, Active, not recruiting, Sponsor: Amgen
Formal studies are needed evaluating the clinical efficacy of intratumoral injection of Flubok Quadrivalent recombinant influenza vaccine in CSCCs as well as other tumors. Trial primary completion date: Jan 2021 --> May 2020
- || Imlygic (talimogene laherparepvec) / Amgen
New P1/2 trial, Metastases: TVEC and Preop Radiation for Sarcoma (8 ml Dose) (clinicaltrials.gov) - Oct 22, 2020
P1/2, N=46, Recruiting, Sponsor: Varun Monga, MD
- | Imlygic (talimogene laherparepvec) / Amgen
Journal, Oncolytic Virus: OvirusTdb: A database of oncolytic viruses for the advancement of therapeutics in cancer. (Pubmed Central) - Oct 21, 2020
Recently, the FDA approved an oncolytic virus T-vec for the treatment of melanoma...Nearly, 3243 and 1506 records indicate cancer cell death via apoptosis induction and immune activation, respectively. OvirusTdb may facilitate researchers in designing and discovering new oncolytic viruses for effective cancer treatment.
- | Imlygic (talimogene laherparepvec) / Amgen
Journal: An Evaluation of Talimogene Laherparepvec for the Treatment of Melanoma. (Pubmed Central) - Oct 16, 2020
Clinical applications will likely increase as more data become available on its use in the neoadjuvant setting and in combination with other systemic immune therapies. We expect the fields of intralesional therapy and viral oncotherapy to expand as we better understand how to manipulate the tumor microenvironment and host immune response to cancer.
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTUAL] Tumoral Melanosis Mimicking Residual Melanoma After T-VEC Treatment () - Oct 14, 2020 - Abstract #SITC2020SITC_1619;
Conclusions In patients receiving T-VEC treatment, pathologic CR may be achieved within the first 2–3 months, which precedes clinical improvement of pigmentation. To decrease unnecessary additional T-VEC treatment and assess the response correctly, serial biopsy of stable pigmented lesions should be considered to assess for the presence or absence of viable tumor.
- Imlygic (talimogene laherparepvec) / Amgen, Yervoy (ipilimumab) / Ono Pharma, BMS
[VIRTUAL] Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial () - Oct 14, 2020 - Abstract #SITC2020SITC_1463;
P1b/2
Subsequent anticancer therapies may confound OS analysis. The BRAF mutant post-hoc analysis requires further mechanistic investigation.
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTUAL] 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma () - Oct 14, 2020 - Abstract #SITC2020SITC_1462;
- Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma () - Oct 14, 2020 - Abstract #SITC2020SITC_1459;
P1b
92% of responders remained in response with improved OS observed in responders compared with non-responders. The corresponding randomized phase 3 trial has completed enrollment and is currently ongoing.
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTUAL] A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) () - Oct 14, 2020 - Abstract #SITC2020SITC_1440;
P1
Plasma and urine fluid samples will be analyzed for viral load. Results N/A Conclusions This study will test the safety, tolerability, and preliminary clinical activity of IP TL; the results will be relevant to inform future investigations of local oncoimmunotherapies in patients with PSD, a highly unmet need population that currently has limited therapeutic options.
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTUAL] Tumoral Melanosis Mimicking Residual Melanoma After T-VEC Treatment () - Oct 14, 2020 - Abstract #SITC2020SITC_884;
Conclusions In patients receiving T-VEC treatment, pathologic CR may be achieved within the first 2–3 months, which precedes clinical improvement of pigmentation. To decrease unnecessary additional T-VEC treatment and assess the response correctly, serial biopsy of stable pigmented lesions should be considered to assess for the presence or absence of viable tumor.
- Imlygic (talimogene laherparepvec) / Amgen, Yervoy (ipilimumab) / Ono Pharma, BMS
[VIRTUAL] Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial () - Oct 14, 2020 - Abstract #SITC2020SITC_728;
P1b/2
Subsequent anticancer therapies may confound OS analysis. The BRAF mutant post-hoc analysis requires further mechanistic investigation.
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTUAL] 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma () - Oct 14, 2020 - Abstract #SITC2020SITC_727;
- Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma () - Oct 14, 2020 - Abstract #SITC2020SITC_724;
P1b
92% of responders remained in response with improved OS observed in responders compared with non-responders. The corresponding randomized phase 3 trial has completed enrollment and is currently ongoing.
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTUAL] A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) () - Oct 14, 2020 - Abstract #SITC2020SITC_705;
P1
Plasma and urine fluid samples will be analyzed for viral load. Results N/A Conclusions This study will test the safety, tolerability, and preliminary clinical activity of IP TL; the results will be relevant to inform future investigations of local oncoimmunotherapies in patients with PSD, a highly unmet need population that currently has limited therapeutic options.
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTURL] Preclinical Antitumor Activity of OncoVEXmGM-CSF in Combination with PD-1/PD-L1 Inhibitors in PD-L1 Resistant Mouse Models Supports the MASTERKEY-115 Study () - Oct 14, 2020 - Abstract #SITC2020SITC_301;
- || Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma (clinicaltrials.gov) - Oct 12, 2020
P1b, N=4, Active, not recruiting, Sponsor: West Cancer Center
Results N/A Conclusions This study will test the safety, tolerability, and preliminary clinical activity of IP TL; the results will be relevant to inform future investigations of local oncoimmunotherapies in patients with PSD, a highly unmet need population that currently has limited therapeutic options. Recruiting --> Active, not recruiting | N=20 --> 4 | Trial primary completion date: Jun 2020 --> Nov 2020
- || Imlygic (talimogene laherparepvec) / Amgen
Clinical, Journal: Talimogene laherparepvec (T-VEK) use in kidney transplant recipient. (Pubmed Central) - Oct 10, 2020
Recruiting --> Active, not recruiting | N=20 --> 4 | Trial primary completion date: Jun 2020 --> Nov 2020 No abstract available
- | Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Journal: Talimogene Laherparepvec plus Pembrolizumab Is Effective in Sarcomas. (Pubmed Central) - Oct 9, 2020
No abstract available Pembrolizumab with the oncolytic virus talimogene laherparepvec was effective in treating sarcomas.
- | Imlygic (talimogene laherparepvec) / Amgen
Observational data, Retrospective data, Journal, Real-World Evidence: Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database. (Pubmed Central) - Oct 7, 2020
This real-world prescription database study showed that patients who initiated treatment in 2017 had a treatment duration in clinical practice that corresponded with the European Summary of Product Characteristics guideline of continuing T-VEC for ≥6 months. Additional long-term data linking drug use with clinical outcomes are needed.
- | Imlygic (talimogene laherparepvec) / Amgen, Opdivo (nivolumab) / BMS
Enrollment change, PD(L)-1 Biomarker, IO biomarker: NCI#10057: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (clinicaltrials.gov) - Oct 7, 2020
P2, N=68, Recruiting, Sponsor: National Cancer Institute (NCI)
Additional long-term data linking drug use with clinical outcomes are needed. N=100 --> 68
- [VIRTUAL] Market Access Landscape for Advanced Therapy Medicinal Products in the EU-5 () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1648;
Two ATMPs, Zynteglo and Zolgensma are currently being evaluated by NICE. CONCLUSIONS Most ATMPs are granted patient access in EU5 even though HTA bodies have imposed monitoring requirements to ensure the value reflects the price.
- Imlygic (talimogene laherparepvec) / Amgen, Tecentriq (atezolizumab) / Roche
[VIRTUAL] Solti-1503 PROMETEO: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer () - Oct 2, 2020 - Abstract #SABCS2020SABCS_1115;
P1
We thank ROCHE for their provision of Atezolizumab and their financial contribution to this clinical study. Clinical trial identification: NCT03802604
- Imlygic (talimogene laherparepvec) / Amgen, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
[VIRTUAL] A phase I study of preoperative ipilimumab, nivolumab, and talimogene laherparepvec for localized breast cancer () - Oct 2, 2020 - Abstract #SABCS2020SABCS_1110;
P1
As described above, the projected sample size is 20 patients. Clinical trials identification: NCT04185311.
- Herceptin (trastuzumab) / Roche
[VIRTUAL] The use of magnetic resonance imaging (MRI) in predicting pathological complete response(pCR) in the breast and axilla after the addition of immunotherapy to neoadjuvant systemic therapy (NST) (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_308;
The PPV and NPV of MRI to predict pCR in patients undergoing immunotherapy in combination with NST remains within the ranges described in patients undergoing NST alone. MRI remains a useful tool to guide surgical management but is not accurate enough to replace pathological evaluation.
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date, Surgery, Metastases: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (clinicaltrials.gov) - Oct 1, 2020
P1, N=21, Recruiting, Sponsor: National Cancer Institute (NCI)
MRI remains a useful tool to guide surgical management but is not accurate enough to replace pathological evaluation. Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021
- || Imlygic (talimogene laherparepvec) / Amgen, Opdivo (nivolumab) / BMS
Enrollment open, Trial initiation date, PD(L)-1 Biomarker: NIVEC: Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease (clinicaltrials.gov) - Sep 28, 2020
P2, N=24, Recruiting, Sponsor: The Netherlands Cancer Institute
Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021 Not yet recruiting --> Recruiting | Initiation date: May 2020 --> Sep 2020
- Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] “A Phase II Study of Combining T-VEC (NSC-785349) and Pembrolizumab (NSC-776864) in Pa-tients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy.” () - Sep 25, 2020 - Abstract #SWOGFall2020SWOG_Fall_21;
- || Imlygic (talimogene laherparepvec) / Amgen
Trial completion, Metastases: MASTERKEY 232: Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) (clinicaltrials.gov) - Sep 23, 2020
P1b, N=36, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting | Initiation date: May 2020 --> Sep 2020 Active, not recruiting --> Completed
- Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Complete remission after a combination of PD-1 immunotherapy and oncolytic viruses (ePoster Terminal 2) - Sep 20, 2020 - Abstract #ADO2020ADO_161;
The resulting deficiency of melanocyte ‐ stimulating hormone and the immune response against the melanocytes probably caused the progressive vitiligo. This raises questions about a meaningful immunotherapy sequence and the prognostic value of post-therapeutic vitiligo.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Successful response after re-induction of immunotherapy with nivolumab after Talimogen laherparepvec in metastatic melanoma (ePoster Terminal 2) - Sep 20, 2020 - Abstract #ADO2020ADO_146;
We await the results of the 265 study (pembrolizumab + T-Vec) with great interest, which are currently still pending. Key words: re-induction immunotherapy, T-Vec, malignant melanoma
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Effectiveness of intralesional talimogen Laherparepvec and systemic PD-1 antibody therapy after progress under adjuvant PD-1 antibody therapy in malignant melanoma: 3 case reports (ePoster Terminal 2) - Sep 20, 2020 - Abstract #ADO2020ADO_131;
The combination of pembrolizumab with T-VEC or placebo has already been investigated in patients with AJCC stage IIIB-IVM1d as part of the Masterkey-265 study in the first-line situation; the results are still pending...The first patient also had lung metastasis (M1b), so that a combined immunotherapy with ipilimumab and nivolumab was initiated...Summary: After a progression under adjuvant PD-1 antibody therapy, a combination of T-VEC and PD-1 antibody therapy is possible continues to be a sensible treatment option. In a phase II study, this situation is precisely what happens in patients with not Resectable or metastatic melanoma in AJCC stage IIIB ‐ IVM1d that had progressed under previous PD ‐ 1 antibody therapy was examined (Masterkey ‐ 115).
- || Imlygic (talimogene laherparepvec) / Amgen
Review, Journal: An update on GM-CSF and its potential role in melanoma management. (Pubmed Central) - Sep 16, 2020
Although GM-CSF has been injected into tumors for many years, the efficacy of this has not been tested. There is a strong rationale for GM-CSF as a vaccine adjuvant, but it appears of benefit only for strategies that directly involve DCs, such as intratumor talimogene laherparepvec and vaccines in which DCs are loaded with antigen ex vivo and injected admixed with GM-CSF.
- | Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: Neoadjuvant Combination Immunotherapy for Stage III Melanoma (clinicaltrials.gov) - Sep 9, 2020
P2, N=28, Recruiting, Sponsor: University of Louisville
There is a strong rationale for GM-CSF as a vaccine adjuvant, but it appears of benefit only for strategies that directly involve DCs, such as intratumor talimogene laherparepvec and vaccines in which DCs are loaded with antigen ex vivo and injected admixed with GM-CSF. Not yet recruiting --> Recruiting
- [VIRTUAL] Combination Immunotherapy (IT) and Chemotherapy (CT) Can Improve Pathologic Complete Responses (pCR) in Women with Triple Negative (TNBC) and HER2+ Breast Cancer (BC) but Does Not Improve Predictability for Post Therapy Magnetic Resonance Imaging (MRI) (ePoster Gallery) - Sep 1, 2020 - Abstract #SSO2020SSO_507;
We analyzed 44 TNBC and HER2 NAICT pts from 4 distinct Trx protocols including: (1) 14 TNBC pts treated with intratumoral Talimogene laherparepvec (TVEC) in combination with weekly paclitaxel (T) followed by dose dense Adriamycin and Cytoxan (ddAC); (2) 13 ER+HER2+ pts treated with subcutaneous interferon gamma (IFN-) in combination with weekly T with trastuzumab and pertuzumab (HP); (3), 6 ER-HER2+ pts treated with 3 weeks of HER2 pulsed dendritic cell vaccines (DC1) followed by Taxotere, Carboplatin, and HP; and (4), 11 pts on ISPY2 trial; 8 pts randomized to Trx with pembrolizumab with weekly T followed by ddAC, 1 pt treated with SGN-LIV1A followed by ddAC, and 2 pts treated with durvalumab, and T, followed by ddAC. The addition of IT with standard CT regimens in TNBC and HER2 BC has improved pCR but reduced the predictive capacity of MRI suggesting MRI may not be accurate enough to make further surgical decisions.
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTUAL] Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: A Multi-institutional Experience (Virtual Meeting Room 4) - Sep 1, 2020 - Abstract #SSO2020SSO_77;
After failure of initial systemic IO for unresectable metastatic melanoma patients, treatment with TVEC with/without concurrent IO have an in-field ORR of 43% and an in-field CR of 23%. TVEC with IO as second- or later-line therapy is an efficacious treatment option for these patients.
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTUAL] Primary 2-year Results of Phase 2, Multicenter, Randomized, Open-label Trial of Efficacy and Safety for Talimogene Laherparepvec (T-VEC) Neoadjuvant Treatment Plus Surgery versus Surgery in Patients with Resectable Stage IIIBIVM1a Melanoma (Virtual Meeting Room 4) - Sep 1, 2020 - Abstract #SSO2020SSO_75;
P2
T-cell influx and PD-L1 upregulation after T-VEC tx support a role for the adaptive immune system consistent with the mechanisms of action. NCT02211131.
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTUAL] A retrospective chart review study of realworld use of talimogene laherparepvec in unresectable stage IIIB-IVM1a melanoma in four European countries (ZETA HALL) - Aug 31, 2020 - Abstract #EADOI2020EADO-I_207;
- Imlygic (talimogene laherparepvec) / Amgen
[VIRTUAL] 2-year (yr) results and biomarker analysis of a phase 2, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL) (ZETA HALL) - Aug 31, 2020 - Abstract #EADOI2020EADO-I_206;
- | Imlygic (talimogene laherparepvec) / Amgen
Journal, Oncolytic Virus, PD(L)-1 Biomarker, IO Biomarker: Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. (Pubmed Central) - Aug 30, 2020
P1/2
For clinical use, these viruses are expected to be most effective in combination with other anti-cancer agents, in particular PD1/L1-targeted immune checkpoint blockade. The first virus from this program (expressing GALV-GP-R and hGM-CSF) has entered clinical development alone and in combination with anti-PD1 therapy in a number of tumor types (NCT03767348).
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma. (Pubmed Central) - Aug 28, 2020
Newer options are monoclonal anti-CD40 antibody dacetuzumab, anti-PD-1 and anti-PD-L1 checkpoint inhibitors, and Bruton tyrosine kinase inhibitors...In aggressive PCDLCBCL, LT, rituximab with polychemotherapy is recommended. Innovative therapies include intralesional oncolytic virotherapy, systemic monoclonal antibodies, and small molecules.
- || Imlygic (talimogene laherparepvec) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases (clinicaltrials.gov) - Aug 27, 2020
P1b, N=36, Active, not recruiting, Sponsor: Amgen
Innovative therapies include intralesional oncolytic virotherapy, systemic monoclonal antibodies, and small molecules. Recruiting --> Active, not recruiting | Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: Aug 2020 --> Jan 2021
- | Imlygic (talimogene laherparepvec) / Amgen
Enrollment closed, Combination therapy, Metastases: TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion) (clinicaltrials.gov) - Aug 23, 2020
P1/2, N=15, Active, not recruiting, Sponsor: Royal Marsden NHS Foundation Trust
Recruiting --> Active, not recruiting | Trial completion date: May 2022 --> Aug 2022 | Trial primary completion date: Aug 2020 --> Jan 2021 Recruiting --> Active, not recruiting
- || Imlygic (talimogene laherparepvec) / Amgen
Clinical, Observational data, Journal: Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). (Pubmed Central) - Aug 22, 2020
Discontinuation of T-VEC did not differ by anti-PD-1-based therapy use or timing. In real-world settings, T-VEC may be used concurrently with or after anti-PD-1-based therapy.